β-defensin 8 Inhibitors
β-defensin 8 inhibitors represent a chemical class focused on the selective inhibition of β-defensin 8, a small cationic peptide involved in innate immunity. β-defensins are a family of antimicrobial peptides that contribute to the host defense system by directly disrupting microbial membranes, thereby preventing infection. β-defensin 8, in particular, is known to play a role in the regulation of immune responses and is expressed in various epithelial tissues. Inhibitors targeting β-defensin 8 are designed to modulate its activity and potentially influence its interaction with cellular receptors or signaling pathways. The design and development of these inhibitors involve understanding the structural features of β-defensin 8, such as its conserved cysteine motif and characteristic β-sheet structure, which are crucial for its antimicrobial and immunomodulatory functions. Researchers focus on identifying small molecules, peptides, or peptidomimetics that can specifically bind to β-defensin 8, thereby modulating its functional activity without affecting other defensins or immune peptides.
The synthesis and characterization of β-defensin 8 inhibitors require advanced techniques in chemical biology and structural biochemistry. High-throughput screening methods, computational modeling, and structure-activity relationship (SAR) studies are often employed to discover potent and selective inhibitors. These inhibitors are typically assessed for their ability to bind to β-defensin 8 with high affinity, as well as their capacity to inhibit or modify its function in various in vitro assays. Understanding the precise mechanisms by which these inhibitors interact with β-defensin 8 at a molecular level is essential for further optimizing their selectivity and efficacy. Additionally, researchers may explore the impact of these inhibitors on downstream signaling pathways and cellular processes associated with immune responses. The study of β-defensin 8 inhibitors contributes to a deeper understanding of the complex roles of defensins in immune modulation and their potential as targets for chemical probes in research settings.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR/HER2 inhibitor affecting the MAPK/ERK pathway. Lapatinib indirectly inhibits β-defensin 8 by interfering with the EGFR/HER2/MAPK/ERK pathway, known to modulate β-defensin 8 transcription through specific transcription factors. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
AKT inhibitor disrupting the PI3K/AKT pathway. MK-2206 indirectly suppresses β-defensin 8, as the PI3K/AKT pathway regulates β-defensin 8 transcription through specific transcription factors. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor disrupting PI3K/AKT signaling. LY294002 indirectly suppresses β-defensin 8, as PI3K/AKT signaling regulates β-defensin 8 transcription through specific transcription factors. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor disrupting mTOR signaling. Everolimus indirectly influences β-defensin 8 expression by interfering with the mTOR pathway, known to modulate β-defensin 8 transcription through specific transcription factors. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
p38 MAPK inhibitor affecting the MAPK pathway. SB203580 indirectly inhibits β-defensin 8 by disrupting the p38 MAPK pathway, known to modulate β-defensin 8 transcription through specific transcription factors. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor disrupting PI3K/AKT signaling. Wortmannin indirectly suppresses β-defensin 8, as PI3K/AKT signaling regulates β-defensin 8 transcription through specific transcription factors. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor impacting NF-κB signaling. Bortezomib indirectly hampers β-defensin 8 expression by blocking the proteasome, affecting the degradation of IκB and subsequent NF-κB activation, a pathway known to modulate β-defensin 8 transcription through specific transcription factors. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
H3K27 methyltransferase inhibitor. GSK343 indirectly influences β-defensin 8 by altering histone methylation, impacting the chromatin structure and accessibility of the β-defensin 8 gene for transcription. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
HDAC inhibitor modulating chromatin structure. Trichostatin A indirectly suppresses β-defensin 8 by altering histone acetylation, influencing the accessibility of the β-defensin 8 gene for transcription. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
DNA-damaging agent affecting multiple pathways. Cisplatin indirectly influences β-defensin 8 by causing DNA damage, triggering various stress response pathways that modulate β-defensin 8 transcription through specific transcription factors. | ||||||